Neuronetics and Greenbrook TMS Secure Interim Order for Merger
Neuronetics, Inc. (NASDAQ: STIM) and Greenbrook TMS Inc. have officially received an interim order from the Ontario Superior Court of Justice regarding their proposed merger arrangement. This court decision marks a significant step forward in the planned all-stock transaction between the two companies, where Neuronetics will acquire all outstanding shares of Greenbrook.
Understanding the Interim Order and Shareholder Meetings
The interim order enables the organization of a special meeting for Greenbrook shareholders, where they will have the opportunity to discuss and vote on the merger. This meeting aims to ensure that all shareholders are informed and able to participate in this pivotal decision-making process.
Structure of the Transaction
According to the agreement, each Greenbrook share is set to be exchanged for 0.01149 shares of Neuronetics common stock upon completion of the merger. This exchange ratio is subject to various adjustments that may arise due to interim funding or customary valuations before the arrangement closes. Upon completion, it is projected that Neuronetics shareholders will hold about 57% of the newly formed entity, while Greenbrook shareholders will own approximately 43%.
Unanimous Recommendations from Boards
Both companies' boards have thoroughly reviewed the arrangement. The Greenbrook Board, comprising entirely independent directors, has largely endorsed the transaction, stating that it is in the best interests of shareholders. Both boards urge their respective shareholders to approve the resolutions concerning the merger at the upcoming special meetings.
Scheduled Special Meetings for Shareholders
The Greenbrook Special Meeting is scheduled for a virtual format. Shareholders will be notified accordingly and provided with the necessary materials ahead of time. This type of meeting format is increasingly common as it allows for greater accessibility, ensuring that all stakeholders can participate regardless of their location.
Voting Requirements for the Arrangement
For the arrangement to proceed at the Greenbrook Special Meeting, a two-thirds majority of shareholder votes is required, in addition to a simple majority vote that excludes certain shares. This structured voting process is designed to respect the rights of minority shareholders as well as ensure transparency and fairness in the decision-making process.
Neuronetics Special Meeting Details and Expectations
Likewise, the Neuronetics Special Meeting will occur on the same date in a virtual setting. Stockholders will have the opportunity to review related proxy materials, ensuring they are equipped to make informed decisions regarding the merger. Both companies are committed to open communication and transparency throughout this process.
Overview of Greenbrook TMS
Greenbrook operates numerous treatment centers specializing in Transcranial Magnetic Stimulation (TMS) therapy, providing crucial mental health treatment. This method utilizes electromagnetic stimulation to target areas in the brain associated with mood regulation, serving as an innovative approach to tackling mental health issues.
Neuronetics’ Commitment to Mental Health
Similarly, Neuronetics elevates the standard of care within the mental health realm with its advanced NeuroStar therapy. This non-invasive solution is designed to benefit patients who have not responded to traditional medications, marking a vital advancement in the treatment landscape for mood disorders.
Frequently Asked Questions
What is the significance of the interim order?
The interim order allows for the organization of special shareholder meetings and is a critical step in finalizing the merger between Neuronetics and Greenbrook TMS.
When will the shareholder meetings take place?
Both the Greenbrook and Neuronetics special meetings are scheduled for the same date and will be held virtually.
What are the expected outcomes of the merger?
The merger aims to enhance the capabilities and resources of both companies in the mental health field, ultimately benefiting shareholders and patients alike.
How will shareholder approval be obtained?
A two-thirds majority vote from Greenbrook shareholders and a simple majority from Neuronetics stakeholders are required for the merger to proceed.
What is TMS therapy and who can benefit from it?
TMS therapy is a non-invasive treatment for Major Depressive Disorder and other mental health issues, offering an alternative for individuals who have not found relief through traditional medications.
